Infections in rheumatoid arthritis
Tóm tắt
The purpose of this review is to provide an update concerning recent advances in the evidence- based study of serious infections in patients with rheumatoid arthritis (RA) treated with biological drugs or conventional disease-modifying antirheumatic drugs (DMARDs), concentrating on studies published in the last 18 months.
New studies have further strengthened existing evidence relating the use of biological drugs to serious infections. The risk does not seem to be any different with short-term or long-term use. There is still a lack of conclusive studies identifying biomarkers, but it is plausible that the drugs have direct effects on cytokines and cell activity and then serious infections.
The frequent infections of patients with RA may be due to the disease itself (altered immunological function, disability, immobility, joint surgery), extra-articular manifestations or DMARDs, immunosuppressants and steroids. The use of biological drugs lead to the development of serious infections including tuberculosis. Patients should be informed of their increased risk, and physicians need to be aware of these complications and how to treat them.
Từ khóa
Tài liệu tham khảo
Mikuls, 2002, Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study, Ann Rheum Dis, 61, 994, 10.1136/ard.61.11.994
Doran, 2002, Frequency of infection in patients with rheumatoid arthritis compared with controls. A population-based study, Arthritis Rheum, 9, 2287, 10.1002/art.10524
Atzeni, 2008, Infections and treatment of patients with rheumatic diseases, Clin Exp Rheumatol, 26, S67
Carmona, 2010, Rheumatoid arthritis, Best Pract Res Clin Rheumatol, 24, 733, 10.1016/j.berh.2010.10.001
Brassard, 2006, Antirheumatic drugs and the risk of tuberculosis, Clin Infect Dis, 43, 717, 10.1086/506935
van der Veen, 1994, Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate, Ann Rheum Dis, 53, 224, 10.1136/ard.53.4.224
Wolfe, 2006, Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders, Rheumatology (Oxford), 45, 1370, 10.1093/rheumatology/kel328
Lacaille, 2008, Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis, Arthritis Rheum, 59, 1074, 10.1002/art.23913
Bernatsky, 2007, Antirheumatic drug use and risk of serious infections in rheumatoid arthritis, Rheumatology (Oxford), 46, 1157, 10.1093/rheumatology/kem076
LeMense, 1994, Opportunistic infection during treatment with low dose methotrexate, Am J Respir Crit Care Med, 150, 258, 10.1164/ajrccm.150.1.8025760
Jenks, 2007, Leflunomide-associated infections in rheumatoid arthritis, J Rheumatol, 34, 2201
Wolfe, 2006, Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy, Arthritis Rheum, 54, 628, 10.1002/art.21568
Grennan, 2001, Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery, Ann Rheum Dis, 60, 214, 10.1136/ard.60.3.214
Edwards, 2007, The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis, Arthritis Rheum, 57, 1151, 10.1002/art.23003
Visser, 2009, Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative, Ann Rheum Dis, 68, 1086, 10.1136/ard.2008.094474
Thompson, 2001, Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials, Arthritis Rheum, 63, 1479, 10.1002/art.30310
Lahiri, 2015, Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis, Best Pract Res Clin Rheumatol, 29, 290, 10.1016/j.berh.2015.05.009
Keane, 2008, Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies, Curr Opin Rheumatol, 220, 443, 10.1097/BOR.0b013e3283025ec2
Dittmar, 2014, Human biological research since 2006 at the Christian-Albrechts-University in Kiel: aging, chronobiology, and high altitude adaptation, Anthropol Anz, 71, 143, 10.1127/0003-5548/2014/0392
Winthrop, 2006, Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor, Nat Clin Pract Rheumatol, 2, 602, 10.1038/ncprheum0336
Souto, 2014, Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies, Rheumatology (Oxford), 53, 1872, 10.1093/rheumatology/keu172
Emery, 2009, Golimumab, a human antitumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis, Arthritis Rheum, 60, 2272, 10.1002/art.24638
Keystone, 2012, Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial, Rheumatol Oxford, 51, 1628, 10.1093/rheumatology/kes082
Smolen, 2009, Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial, Ann Rheum Dis, 68, 797, 10.1136/ard.2008.101659
Cantini, 2015, (SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice, Autoimmun Rev, 14, 503, 10.1016/j.autrev.2015.01.011
Mazurek, 2010, Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection: United States, 2010, MMWR Recomm Rep, 59, 1
Arkema, 2016, Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?, Ann Rheum Dis, 4, 1212
Dixon, 2006, Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register, Arthritis Rheum, 54, 2368, 10.1002/art.21978
Listing, 2005, Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis Rheum, 52, 3403, 10.1002/art.21386
Galloway, 2011, Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly, Rheumatology (Oxford), 50, 124, 10.1093/rheumatology/keq242
Strangfeld, 2011, Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?, Ann Rheum Dis, 70, 1914, 10.1136/ard.2011.151043
Atzeni, 2012, Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry, Autoimmun Rev, 12, 225, 10.1016/j.autrev.2012.06.008
Filippini, 2010, Efficacy and safety of antitumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study, Clin Rev Allergy Immunol, 38, 90, 10.1007/s12016-009-8142-1
Singh, 2015, The risk of serious infection with biologics in treating patients with rheumatoid arthritis: a systematic review and meta-analysis, Lancet, 6736, 61704
Davies, 2013, Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK, Ann Rheum Dis, 72, 461, 10.1136/annrheumdis-2012-202228
de La Forest Divonne, 2017, Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers, Joint Bone Spine, 84, 133, 10.1016/j.jbspin.2016.02.028
Burmester, 2017, Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis, Ann Rheum Dis, 76, 414, 10.1136/annrheumdis-2016-209322
Tsiodras, 2008, Fungal infections complicating tumor necrosis factor a blockade therapy, Mayo Clin Proc, 83, 181, 10.1016/S0025-6196(11)60839-2
Alvarez, 2011, Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents, Curr Opin Pulm Med, 17, 172, 10.1097/MCP.0b013e3283455c0b
Smith, 2009, Endemic fungal infections in patients receiving tumor necrosis factor-α inhibitor therapy, Drugs, 69, 1403, 10.2165/00003495-200969110-00002
Liao, 2016, Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications, Clin Microbiol Infect, 22, 815, 10.1016/j.cmi.2016.05.030
Goodman, 2015, Arthroplasty in patients with established rheumatoid arthritis (RA): mitigating risks and optimizing outcomes, Best Pract Res Clin Rheumatol, 29, 628, 10.1016/j.berh.2015.09.004
Del Pozo, 2009, Clinical practice. Infection associated with prosthetic joints, N Engl J Med, 361, 787, 10.1056/NEJMcp0905029
Zimmerli, 2012, Pathogenesis and treatment concepts of orthopaedic biofilm infections, FEMS Immunol Med Microbiol, 65, 158, 10.1111/j.1574-695X.2012.00938.x
Mc Conoughey, 2014, Biofilms in peri prosthetic orthopedic infections, Future Microbiol, 9, 987, 10.2217/fmb.14.64
Goodman, 2016, Management of perioperative tumour necrosis factor a inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis, Rheumatology(Oxford), 55, 573
Galloway, 2011, Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis, 70, 1810, 10.1136/ard.2011.152769
Goh, 2012, Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence, Rheumatol Int, 3, 5, 10.1007/s00296-011-2040-6
Mabille, 2016, Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha, Joint Bone Spine
Atzeni, 2016, Infections and biological therapy in patients with rheumatic diseases, IMAJ, 18, 164
Che, 2014, Risk of herpes/herpes zoster during antitumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis, Joint Bone Spine, 81, 215, 10.1016/j.jbspin.2013.07.009
Harpaz, 2008, Prevention of herpes zoster, MMWR Morb Mortal Wkly Rep, 50, 1
Wendling, 2005, Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy, Ann Rheum Dis, 64, 788, 10.1136/ard.2004.031187
Pérez-Alvarez, 2011, Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases, Medicine (Baltimore), 90, 359, 10.1097/MD.0b013e3182380a76
Cantini, 2014, HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-α) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis, Int J Rheumatol, 926836
Viganò, 2012, Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management, Expert Opin Biol Ther, 12, 193, 10.1517/14712598.2012.646986
Alter, 2012, Epidemiology of hepatitis C virus infection, World J Gastroenterol, 13, 2436, 10.3748/wjg.v13.i17.2436
Parke, 2004, Antitumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection, Arthritis Rheum, 51, 800, 10.1002/art.20702
Zein, 2005, Etanercept as an adjuvant to interferon and ribavirin in treatment naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study, J Hepatol, 42, 315, 10.1016/j.jhep.2004.11.025
Atzeni, 2013, Long-term safety of abatacecpt in patients with rheumatoid arthritis, Autoim Rev, 12, 1115, 10.1016/j.autrev.2013.06.011
Weinblatt, 2006, Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study, Arthritis Rheum, 54, 2807, 10.1002/art.22070
Lee, 2014, Tofacitinib versus methotrexate in rheumatoid arthritis, N Engl J Med, 370, 2377, 10.1056/NEJMoa1310476
Furst, 2012, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012, Ann Rheum Dis, 72, ii2, 10.1136/annrheumdis-2011-201036
Campbell, 2011, Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials, Rheumatology (Oxford), 50, 552, 10.1093/rheumatology/keq343
Salliot, 2009, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Ann Rheum Dis, 68, 25, 10.1136/ard.2007.083188
Lahaye, 2016, Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry, Rheumatology (Oxford), 55, 874, 10.1093/rheumatology/kev437
Winthrop, 2014, Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis, Arthritis Rheumatol, 66, 2675, 10.1002/art.38745
Curtis, 2016, Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis, Ann Rheum Dis, 75, 1843, 10.1136/annrheumdis-2016-209131
Gottenberg, 2010, Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry, Arthritis Rheumatol, 62, 2625, 10.1002/art.27555
Hirao, 2009, Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab, Ann Rheum Dis, 68, 654, 10.1136/ard.2008.090068
Viganò, 2014, Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy, Expert Opin Biol Ther, 14, 1019, 10.1517/14712598.2014.912273
Varisco, 2016, Low risk of hepatitis B virus reactivation in HBsAgnegative/Anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study, J Rheumatol, 43, 869, 10.3899/jrheum.151105
Padovan, 2016, Safety of abatacept in rheumatoid arthritis patients with serological evidence of past or present hepatitis B infection, Arthritis Care Res, 68, 738, 10.1002/acr.22786
Lin, 2013, Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis, J Microbiol Immunol Infect, 46, 65, 10.1016/j.jmii.2011.12.020
Ferri, 2011, Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature, Autoimmun Rev, 11, 48, 10.1016/j.autrev.2011.07.005
Mahajan, 2010, Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection, J Clin Rheumatol, 16, 332, 10.1097/RHU.0b013e3181f4cd92